Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells

Clinical Cancer Research

Volumn 4, Issue 4, 1998, Pages 901-912

  Uckun, Fatih M ^a   Narla, Rama Krishna ^a   Jun, Xiao ^a   Zeren, Tamer ^b   Venkatachalam, Taracad ^a   Waddick, Kevin G ^a,b   Rostostev, Alexander ^a   Myers, Dorothea E ^a  

^a Department of Genetics   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENISTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT EPIDERMAL GROWTH FACTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; LIGAND BINDING; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; BREAST NEOPLASMS; DNA FRAGMENTATION; EPIDERMAL GROWTH FACTOR; FEMALE; GENISTEIN; HUMANS; MIDDLE AGED; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0031921085     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Wood, W. C. Progress from clinical trials on breast cancer. Cancer (Phila.), 74: 2606-2609, 1994.
2. Bonadonna, G., Zambetti, M., and Valagussa, P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results. J. Am. Med. Assoc., 273: 542-547, 1995.
3. Ingle, J. N., Foley, J. F., Mailliard, J. A., Krook, J. E., Hartmann, L. C., Jung, S. H., Veeder, M. H., Gesme, D. H., Jr., Hatfield, A. K., and Goldberg, R. M. Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer. Cancer (Phila.), 73: 2337-2343, 1994.
4. Somlo, G., Doroshow, J. H., Forman, S. H., Leong, L. A., Margolin, K. A., Morgan, R. J., Jr., Raschoko, J. W., Akkman, S. A., Ahn, C., and Nagasawa, S. High-dose doxorubicin, etoposide and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. Cancer (Phila.), 73: 1678-1685, 1994.
5. Abrams, J. S., Moore, T. D., and Friedman, M. New chemotherapeutic agents for breast cancer. Cancer (Phila.), 84: 1164-1176, 1994.
6. Carpenter, G., and Cohen, S. Epidermal growth factor. J. Biol. Chem., 265: 7709-7712, 1990.
7. George-Nacimento, C., Gyenes, A., Halloran, S. M., Merryweather, J., Valenzuela, P., Steimer, K. S., Masiarz, F. R., and Randolph, A. Characterization of recombinant human epidermal growth factor produced in yeast. Biochemistry, 27: 797-802, 1988.
8. Khazaie, K., Schirrmacher, V., and Lichtner, R. B. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev., 12: 255-274, 1993.
9. Mendelsohn, J., and Baselga, J. Antibodies to growth factors and receptors. In: Biologic Therapy of Cancer: Principles and Practice, pp. 607-623. Philadelphia: J. B. Lippincott Co., 1995.
10. Earp, H. S., Dawson, T. L., Li, X., and Yu, H. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat., 35: 115-132, 1995.
11. Wright, J. D., Reuter, C. W., Weber, M. J. An incomplete program of cellular tyrosine phosphorylations by kinase-defective epidermal growth factor receptors. J. Biol. Chem., 270: 12085-12093, 1995.
12. Broome, M. A., Hunter, T. Requirement for c-Src catalytic activity and the SH3 domain in platelet-derived growth factor BB and epidermal growth factor mitogenic signaling. J. Biol. Chem., 271: 16798-16806, 1996.
13. Muthuswamy, S. K. Mammary tumors expressing the neu protooncogene possess elevated cSrc tyrosine kinase activity. Mol. Cell. Biol., 14: 735-743, 1994.
14. Ottenhoff-Kalff, A. K., Rijksen, G., van Beurden, E. A., Hennipman, A., Michels, A. A., and Staal, G. E. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-Src oncogene product. Cancer Res., 52: 4773-4778, 1992.
15. Toi, M., Osaki, A., Yamada, H., and Toge, T. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur. J. Cancer, 27: 977-980, 1991.
16. Chrysogelos, S. A., and Dickson, R. B. EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res. Treat., 29: 29-40, 1994.
17. Flx, S. B. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat., 29: 41-49, 1994.
18. Uckun, F. M., Evans, W. E., Forsyth, C. J., Waddick, K. G., Tuel-Ahlgren, L., Chelstrom, L. M., Burkhardt, A., Bolen, J., and Myers, D. E. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinase. Science (Washington DC), 267: 886-891, 1995.
19. Myers, D. E., Jun, X., Waddick, K. G., Forsyth, C., Chelstrom, L. M., Gunther, R. L., Turner, N. E., Bolen, J., and Uckun, F. M. Membrane-associated CD19-LYN complex is an endogenous p53-independent and bcl-2 independent regulator of apoptosis in human B-lineage lymphoma cells. Proc. Natl. Acad. Sci. USA, 92: 9575-9579, 1995.
20. Feng, R., Konishi, Y., Bell, A. W. High accuracy molecular weight determination and variation, characterization of proteins up to 80 KU by ion spray mass spectrometry. J. Am. Soc. Mass Spectrom., 2: 387-401, 1991.
21. Covey, T. R., Bonner, R. S., Shushan, B. I., and Henion, J. D. Determination of protein oligonucleotides and peptide molecular weights by ion spray mass spectrometry. Rapid Commun. Mass Spectrom., 2: 249-256, 1988.
22. Uckun, F. M., Myers, D. E., Fauci, A. S., and Ambrus, J. L. Leukemic B-cell precursors constitutively express functional receptors for human interleukin-1. Blood, 74: 761-766, 1989.
23. Uckun, F. M., Burkhardt, A. L., Jarvis, L., Jun, X., Stealey, B., Dibirdik, I., Myers, D. C., Tuel-Ahlgren, L., and Bolen, J. B. Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. J. Biol. Chem., 268: 21172-21184, 1993.
24. Uckun, F. M., Waddick, K. G., Mahajan, S., Jun, X., Takata, M., Bolen, J., and Kurosaki, T. Bruton's tyrosine kinase as a mediator of radiation-induced apoptosis in B-lineage lymphoid cells. Science (Washington DC), 22: 1096-1100, 1996.
25. Fry, D. W., Kraker, A., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (Washington DC), 265: 1093-1095, 1994.
26. Tanaka, S., Okabe, T., Chieda, S., Endo, K., Kanoh, T., Okura, A., and Yosida, E. BE-23372M, a novel and specific inhibitor for epidermal growth factor receptor kinase. Jpn. J. Cancer Res., 85: 253-259, 1994.
27. Reddy, K. B., Mangold, G. L., Tandon, A. K., Yoneda, T., Mundy, G. R., Zilberstein, A., and Osborne, C. K. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res., 52: 3636-3641, 1992.
28. Yaish, P., Gazit, A., Gilon, C., Levitzki, A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science (Washington DC), 242: 933-935, 1988.
29. Lyall, R. M., Zilberstein, A., Gazit, A., Gilon, C., Levitzki, A., and Schlessinger, J. Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. J. Biol. Chem., 264: 14503-14509, 1989.
30. Moyer, J. D., Barbacci, E. G., Iwata, K. K., Arnold, L., Boman, B., Cunningham, A., DiOrio, C., Doty, J., Morin, M. J., Moyer, M. P., Neveu, M., Pollack, V. A., Pustilnik, L. R., Reynolds, M. M., Sloan, D., Theleman, A., and Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res., 57: 4838-4848, 1997.
31. Ennis, B. W., Lippman, M. E., and Dickson, R. B. The EGF receptor system as a target for antitumor therapy. Cancer Invest., 9: 553-562, 1991.
32. Harns, A. L. The epidermal growth factor receptor as a target for therapy. Cancer Cells (Cold Spring Harbor), 2: 321-323, 1990.
33. Baselga, J., and Mendelsohn, J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res. Treat., 29: 127-138, 1994.
34. Schmidt, M., Vakalopoulou, E., Schneider, D. W., and Weiss, W. Construction and functional characterization of scFv(14E1)-ETA-a novel, highly potent antibody-toxin specific for the EGF receptor. Br. J. Cancer, 75: 1575-1584, 1997.